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latelets release preformed mediators and generate
eicosanoids that regulate acute hemostasis and in-
ﬂammation, but these anucleate cytoplasts are not
thought to synthesize proteins or cytokines, or to inﬂuence
inﬂammatory responses over time. Interrogation of an ar-
rayed cDNA library demonstrated that quiescent platelets
contain many messenger RNAs, one of which codes for
 
interleukin 1
 
 
 
 precursor (pro–IL-1
 
 
 
). Unexpectedly, the
mRNA for IL-1
 
 
 
 and many other transcripts are constitu-
tively present in polysomes, providing a mechanism for
rapid synthesis. Platelet activation induces rapid and sus-
tained synthesis of pro–IL-1
 
 
 
 protein, a response that is
P
 
abolished by translational inhibitors. A portion of the IL-
1
 
 
 
 is shed in its mature form in membrane microvesicles,
and induces adhesiveness of human endothelial cells for
neutrophils. Signal-dependent synthesis of an active cyto-
kine over several hours indicates that platelets may have
previously unrecognized roles in inﬂammation and vascu-
 
lar injury. Inhibition of 
 
 
 
3
 
 integrin engagement markedly
attenuated the synthesis of IL-1
 
 
 
, identifying a new link
between the coagulation and inﬂammatory cascades, and
suggesting that antithrombotic therapies may also have
novel antiinﬂammatory effects.
 
Introduction
 
Platelets are anucleate blood cells that are required for hemo-
 
stasis, and also participate in pathologic thrombotic syndromes.
Additionally, platelets have inflammatory actions and are a
rich source of chemokines, cytokines, and growth factors that
are preformed and packaged in storage granules (Klinger,
1997). After platelet activation, these mediators influence
 
wound surveillance, repair, and vascular remodeling by signal-
ing target cells and inducing leukocyte accumulation (Weyrich
et al., 1996; Mannaioni et al., 1997; Barry and FitzGerald,
1999). Activated platelets also synthesize eicosanoids from
arachidonic acid released from membrane phospholipids, a
process that contributes to inflammation and thrombosis
(Barry et al., 1997, 1999; Barry and FitzGerald, 1999). Secre-
tion of granular proteins and eicosanoid generation are rapid
processes that occur within minutes after platelet activation.
 
Platelets are thought to play a minor role, if any, in ongo-
ing inflammation or vascular injury and repair beyond initial
adhesion, secretion, and eicosanoid synthesis. However, acti-
vation of platelets does not appear to decrease their life span
(Reimers et al., 1976; Michelson et al., 1996; Berger et al.,
1998), and thrombogenic adhesive platelets remain func-
tional (Berger et al., 1998). This observation suggests that ac-
 
tivated platelets may contribute to thrombotic and inflam-
matory cascades for much longer periods than previously
believed. Consistent with this notion, we recently demon-
strated that activated platelets translate constitutive mRNAs
into proteins, and that this process continues for hours after
stimulation with thrombin- or integrin-mediated adhesion
(Weyrich et al., 1998; Pabla et al., 1999). In this report, we
use a model of platelet–fibrin clot formation to demonstrate
for the first time that activated platelets synthesize an in-
 
flammatory cytokine, interleukin (IL)*-1
 
 
 
. Accumulation of
 
IL-1
 
 
 
 is prolonged, attenuated by blocking engagement
 
of 
 
 
 
3
 
 integrins, and mediates signaling of endothelial cells
with consequent neutrophil (polymorphonuclear leukocyte
[PMN]) adhesion. It was reported earlier that stimulated
platelets possess IL-1
 
 
 
 activity, but they were not thought to
actively synthesize this inflammatory protein (Hawrylowicz
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et al., 1989; Loppnow et al., 1998). Regulated cytokine syn-
thesis establishes the potential for previously unrecognized bi-
ologic roles for platelets in inflammation and vascular injury.
 
Results and discussion
 
The mRNA for IL-1
 
 
 
 and other transcripts are 
associated with the polysomes of resting platelets
 
We extracted mRNA from resting platelets and identified
constitutively present transcripts using an arrayed cDNA li-
brary. Interrogation of 588 cDNAs demonstrated that nu-
merous mRNAs are present in resting platelets (Fig. 1 A).
Table I is an abbreviated list of these mRNAs, highlighting
transcripts for which the corresponding protein has been re-
ported in platelets. The hybridization patterns were similar
among different platelet donors (unpublished data) and
identical when mRNA from resting platelets and platelets
activated with thrombin were examined, indicating that as
expected, there was no new transcription (unpublished
data). The mRNA for IL-1
 
 
 
 was one of the constitutive
transcripts in unstimulated platelets (Fig. 1, A and B; Table
I). Leukocyte-specific transcripts were not detected, indicat-
ing that platelets were the source of IL-1
 
 
 
 mRNA and pro-
tein (see below) in our assays (Fig. 1 B; Table I).
We examined the monosome and polysome fractions
from platelets and found that ribosomal profiles for resting
and activated cells paralleled each other, and that ribosomal
RNA is primarily located in monosomal fractions. In con-
trast, IL-1
 
 
 
 transcripts were located in the polysomes of rest-
ing and activated platelets (Fig. 1 C), as were many other
mRNAs (unpublished data). Thrombin activation did not
alter the distribution of IL-1
 
 
 
 mRNA in monosomes and
polysomes (Fig. 1 C and unpublished data). These results
Figure 1. mRNA for IL-1  is present in platelets and associated 
with polysomes. (A) Total RNA from quiescent platelets was iso-
lated and analyzed using an arrayed cDNA library. The circle indi-
cates duplicate hybridizations with the cDNA for pro–IL-1 . 
(B) Total RNA from resting platelets (pl) or lipopolysaccharide-
stimulated monocytes (mo) was isolated and analyzed by reverse 
transcription PCR for COX-1, IL-8, GM-CSF, ENA-78, Bcl-3, or 
IL-1 . (C) The ribosomal profiles of resting platelets (left) or platelets 
activated with thrombin (0.1 U/ml; 1 h) (right) were determined (see 
Materials and methods). 28S and 18S rRNA and mRNA for IL-1  
and GAPDH were assayed in each ribosomal fraction. Fractions 1–3 
contain monosomes and low-order polysomes, and fractions 4–6 
contain higher order polysomes. This figure is representative of 
three independent experiments.
 
Table I. 
 
mRNAs expressed in human platelets
Platelet-derived mRNAs
 
23-kD highly basic protein
40S ribosomal protein S9
Apoptosis inhibitor survivin
 
 
 
-Actin
Cadherin 4
Caspase-2 precursor
Caspase-3
Caspase-4 precursor
CD9 antigen
Cell apoptosis susceptibility protein
Collagen 6 
 
 
 
 subunit
Cytosolic superoxide dismutase 1 (SOD1)
GAPDH
Glutathione 
 
S
 
-transferase
GPIIIa (CD61)
Hepatoma-derived growth factor
Histocompatibility leukocyte antigen class I HLA-C allele HLA-4
IL-1
 
 
 
 precursor
IL-10 precursor
Integrin-linked kinase (ILK) 
Insulin-like growth factor 1A
Lamin 
 
 
 
 4 subunit
Low density lipoprotein receptor related protein 2
Osteonectin
p38 mitogen-activated protein kinase
Paxillin
Platelet-derived growth factor A (PDGF-A)
Phospholipase A2
Platelet basic protein precursor
RHO GDI 
 
 
 
RHO GDI 
 
 
 
Tissue inhibitor of metalloproteinase 1 (TIMP-1) 
Tubulin 
 
 
 
1
Ubiquitin
Ubiquitin conjugating enzyme
Vascular endothelial growth factor receptor 1 (VEGF-R1)
Vimentin 
Activated platelets synthesize interleukin 1
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were unexpected, as a shift from monosomes to polysomes is
characteristic of translational control at the level of polypep-
tide initiation, an important posttranscriptional regulatory
mechanism (Kaspar and Gehrke, 1994; Sachs et al., 1997).
Thus, platelets have translational checkpoints and control
mechanisms beyond chain initiation as reported for Nanos
in 
 
Drosophila
 
 embryos (Clark et al., 2000), and for IL-1
 
 
 
 in
mononuclear leukocytes under certain conditions of stimu-
lation (Kaspar and Gehrke, 1994). Such translational con-
trol mechanisms may be specialized for rapid synthesis of
critical transcripts (Clark et al., 2000).
 
IL-1
 
 
 
 mRNA is translated into protein by activated 
platelets during fibrin clot formation
 
Next, we examined expression of the IL-1
 
 
 
 gene product in
resting platelets by immunocytochemistry, and found nei-
ther the precursor nor the mature form (Fig. 2, A, top left, B,
and Fig. 3). In contrast, IL-1
 
 
 
 was robustly detected in com-
plexes of platelets and fibrin after activation with thrombin
in the presence of fibrinogen, a model of clot formation and
retraction (Fig. 2 A, top right). The result is consistent with
previous reports that IL-1
 
 
 
 activity is present in stimulated
platelets (Hawrylowicz et al., 1989; Loppnow et al., 1998).
Pretreatment of platelets with puromycin, a translational in-
hibitor, completely inhibited IL-1
 
 
 
 synthesis (Fig. 2, A, bot-
tom left, B, and C). However, platelet–fibrin clumps formed
in response to thrombin, indicating that puromycin was not
nonspecifically toxic. Similarly, staining of parallel samples
for P-selectin, which is constitutively stored in 
 
 
 
-granules,
was unchanged by pretreatment with puromycin, indicating
that this translational inhibitor did not alter the detection of
resident proteins (Fig. 2 A, bottom right). When platelets
were stimulated with thrombin in the presence of fibrinogen,
IL-1
 
 
 
 and P-selectin were associated with the fibrin lattice
(Fig. 2 A), consistent with a previous report for P-selectin
distribution (Siljander et al., 1996) (also see below).
We confirmed that IL-1
 
 
 
 is synthesized by activated
platelets by incubating them with [
 
35
 
S]methionine, stimulat-
ing them with thrombin, and immunoprecipitating labeled
proteins with an antibody that preferentially recognizes IL-
1
 
  
 
precursor (pro–IL-1
 
 
 
). This process yielded a 32-kD
band, which coincides with the expected mass of pro–IL-1
 
 
 
(Fig. 2 C). This labeled product was absent in thrombin-
stimulated platelets that were pretreated with puromycin.
Puromycin also completely inhibited accumulation of pro–
and mature IL-1
 
 
 
 when measured by ELISA, indicating that
it inhibits synthesis and not conversion of pro–IL-1
 
 
 
 into its
mature form (Fig. 2 B).
We next measured IL-1
 
 
 
 levels in resting and activated
platelets over an extended time period. Accumulation of
pro–IL-1
 
 
 
 was sustained over hours and was followed by
processing of the precursor into its mature, active form (Fig.
3 A). Pro–IL-1
 
 
 
 was detectable in thrombin-stimulated
 
in the presence of [
 
35
 
S]methionine for 8 h. The cells were then lysed 
and the proteins were immunoprecipitated with an antibody that 
preferentially recognizes pro–IL-1
 
 
 
. A single labeled protein with a 
molecular mass corresponding to pro–IL-1
 
 
 
 was identified (arrow). 
A second experiment yielded a similar result. Bars, 10 
 
 
 
m.
 
Figure 2.
 
IL-1
 
 
 
 is synthesized by platelets in fibrin clots.
 
 
(A) Immunolocalization of IL-1
 
 
 
 or P-selectin with actin in resting 
platelets (Baseline) or platelets activated with thrombin (0.1 U/ml) 
after pretreatment with puromycin (100 
 
 
 
M) or control buffer. 
Freshly isolated platelets were incubated as indicated for 8 h and 
examined by immunocytochemical analysis. Red immunofluores-
cence is staining for IL-1
 
 
 
 (top right) or P-selectin (bottom right). 
Green immunofluorescence is staining for actin. In online supple-
mental Fig. S1, immunostaining for IL-1
 
 
 
 was quenched when the 
antibodies were preincubated with purified IL-1
 
 
 
 protein (http://
www.jcb.org/cgi/content/full/154/3/485/DC1). Representative of 
five independent experiments. (B) Total IL-1
 
 
 
 (mean 
 
  
 
SEM, 
 
n
 
 
 
  
 
6) 
synthesized by resting platelets (Co) or platelets activated with 
thrombin (IIa) (8 h) in the presence or absence of puromycin (Puro; 
100 
 
 
 
M) was determined by ELISA. (C) Platelets were pretreated 
with puromycin or DMSO, activated with thrombin, and incubated  
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platelets within 30 min (unpublished data), a rapid synthetic
response that may result from localization of IL-1
 
 
 
 tran-
scripts in polysomes in resting platelets (see above) (Clark et
al., 2000). Platelets synthesized IL-1
 
 
 
 in every experiment
(
 
n 
 
 
 
 30), although the magnitude was variable among do-
nors (unpublished data). This variability was not likely to be
due to contaminating leukocytes, as we did not detect mac-
rophage colony stimulating factor (M-CSF) (60 
 
  
 
13 vs. 69 
 
 
 
1 pg/ml in control vs. activated cells [18 h], respectively),
a monocyte-derived cytokine. In addition, we detected no
increase in IL-1
 
 
 
 protein levels when lymphocytes or mono-
cytes were added to isolated platelets, concentrations of
which were 10-fold greater than the trace numbers of leuko-
 
cytes that were sometimes detected in our preparations (un-
published data). Platelet-activating factor (PAF) also in-
duced IL-1
 
 
 
 synthesis (Fig. 3 B) as did ADP, collagen, and
epinephrine (Fig. 3 C). Together, Figs. 1–3 demonstrate
that platelets synthesize an important cytokine, IL-1
 
 
 
, and
have the potential to influence inflammatory events over
several hours by activation-induced translation of a cytokine
from constitutive mRNA.
 
IL-1
 
  
 
synthesized by activated platelets signals 
endothelial cells and induces PMN adhesion
 
Approximately 60% of mature IL-1
 
 
 
 is retained within the
platelets or the fibrin mesh that surrounds aggregated plate-
lets (Fig. 2 A). The remaining IL-1
 
 
 
 is found in the extracel-
lular milieu. Fractionation of the supernatant revealed that
half of the IL-1
 
 
 
 was associated with platelet microvesicles, a
finding confirmed by assay of  3 integrins and P-selectin in
the same samples (Fig. 4 A and unpublished data). The re-
maining IL-1  in the supernatant fraction was completely
soluble (Fig. 4 A). Soluble and microvesicle-associated IL-1 
delivered outside-in signals to human endothelial cells and
induced their adhesiveness for neutrophils (Fig. 4 B and
unpublished data), a response dependent on synthesis of
E-selectin, intercellular adhesion molecule 1, and chemokines
(McEver et al., 1998). However, IL-1  exported in microves-
icles was at least fivefold more potent than soluble IL-1  when
equivalent volumes of sample were tested (unpublished
data), suggesting that other inflammatory mediators pack-
aged in microvesicles (Barry et al., 1999) may act in concert
with IL-1  to induce endothelial adhesiveness. In this re-
gard, we recently found that IL-1  acts in concert with
P-selectin to induce expression of cyclooxygenase (COX)-2
when human monocytes interact with activated platelets
(unpublished data). Recombinant IL-1  receptor antagonist
inhibited the response to platelet-derived IL-1  and purified
IL-1 , but did not inhibit adhesiveness induced by tumor
necrosis factor   (Fig. 4 B and unpublished data). These
data indicate that IL-1  synthesized by activated platelets
induces inflammatory responses of target endothelial cells.
 3 integrins regulate IL-1  synthesis by platelets
In this model of clot formation and maturation, IL-1  is
synthesized by platelets as they associate with the fibrin
network (Fig. 2 A). Therefore, we pretreated platelets with
mAb c7E3, an antibody that interrupts engagement of in-
tegrins  IIb 3 and  V 3 and prevents the retraction of the
fibrin mesh (Coller, 1985; Pabla et al., 1999). We found
that pretreatment with c7E3 inhibited clot retraction,
whereas a panel of control antibodies had no effect (Fig. 4
C, inset, and unpublished data). In addition, IL-1  levels
were markedly reduced when platelets were pretreated with
c7E3, compared with those treated with a control antibody
in parallel (Fig. 4 C). These results indicate that  3 inte-
grins transmit outside-in signals to translational mecha-
nisms that regulate IL-1  synthesis, and suggest that some
of the therapeutic benefits of blocking  3 integrin engage-
ment may result from interrupting consequent inflamma-
tory responses.
Although the exact mechanisms are not yet clear, integrins
may regulate translation in platelets at checkpoints indepen-
Figure 3. Platelet agonists trigger prolonged IL-1  accumulation in 
fibrin complexes. Platelets were activated with thrombin (0.1 U/ml) 
(A) or PAF (1 nM) (B) in the presence of fibrinogen for the designated 
time periods. Precursor and mature IL-1  were measured by ELISA. 
These data are the mean   SEM for four independent experiments. 
(C) Control platelets or cells activated with thrombin (0.1 U/ml), ADP 
(20  M), collagen (200  g/ml), or epinephrine (10  M) were incu-
bated for 18 h and IL-1  was assayed (mean   SEM; n   4).Activated platelets synthesize interleukin 1  | Lindemann et al. 489
dent of initial ribosomal mRNA interactions, as IL-1  tran-
scripts are constitutively present in platelet polysomes (see
above). In parallel experiments we have found that transla-
tional control proteins are physically separate from mRNAs
in resting platelets, and that integrin engagement redistrib-
utes these proteins to mRNA-rich areas (Lindemann et al.,
2001). Dissection of mechanisms of signal-dependent syn-
thesis of specific gene products such as IL-1  by platelets
may yield new insights into translational control in special-
ized cells (Weyrich et al., 1998; Clark et al., 2000) and re-
veal new activities of platelets in atherogenesis, tissue remod-
eling, and tumor angiogenesis (Weyrich et al., 1996; Barry
et al., 1997; Mannaioni et al., 1997; Pinedo et al., 1998).
Materials and methods
Platelet isolation
Washed platelets were isolated from acid-citrate-dextrose–anticoagulated
human blood as described previously (Weyrich et al., 1996). Platelets (5  
10
8 total) were resuspended in M199 medium containing 100  g/ml of fi-
brinogen, and were left quiescent or stimulated with thrombin, PAF, ADP,
collagen, or epinephrine for 0.5–18 h. In selected experiments, platelets
were pretreated with mAb c7E3 (ReoPro [Abciximab]; Lilly), control anti-
bodies, or puromycin. After each time point, the platelets were pelleted by
centrifugation and the supernatant was collected. The pellet was lysed in
0.5 ml of RIPA buffer. The lysate and supernatant were stored in aliquots at
 20 C until further use.
Polysome analysis
Polysomes were isolated from platelets using minor modifications of pub-
lished protocols (Kaspar and Gehrke, 1994). In brief, platelets (7.5   10
9)
were lysed in a high-salt buffer to remove polysomes from the cytoskeleton
(200 mM Tris, 520 mM KCl, 30 mM MgCl2, 4% Triton X-100, and 200 mM
sucrose, pH 9.5). The cells were passed three times through a 21-gauge tu-
berculin syringe, followed by a brief centrifugation to remove all insoluble
material and heparin (10 mg/ml), and NaCl (150 mM) was added to the ly-
sate. Mitochondria were removed by further centrifugation (5 min, 14,000 g)
and the resulting supernatant was placed on a 4-ml sucrose gradient
(0.5–2 M) and centrifuged at 4 C for 2 h (43,700 rpm) using an SW55 Ti
swinging bucket rotor (Beckman Coulter).
Sucrose gradients were fractionated using an ISCO UA-6 254-nm con-
tinuous flow chamber into 760- l aliquots. Total RNA in each fraction was
isolated for analysis of ribosomal RNA and mRNA for IL-1  and glutaralde-
hyde 3-phosphate dehydrogenase (GAPDH) as described previously (Wey-
rich et al., 1998). The total mRNA pool in platelets was also determined by
interrogation of cDNA libraries according to the manufacturer’s instruc-
tions (array 7742-1; CLONTECH Laboratories, Inc.). In selected experi-
ments, sucrose cushions were used to isolate mRNAs associated with poly-
somes of resting and thrombin-activated platelets as described previously
(Davies and Abe, 1995). The sucrose cushion was based on ribosomal pro-
files from complete sucrose gradients that were fractionated with the ISCO
continuous flow chamber (see above).
ELISA
ELISAs for pro–IL-1 , mature IL-1 , and M-CSF were performed accord-
ing to the manufacturer (R&D Systems; Bender Med Systems). The pro–
and mature IL-1  ELISAs did not cross react with one another.
Immunoprecipitation of
[
35S]methionine–labeled proteins
Immunoprecipitation of metabolically labeled IL-1  was conducted as de-
scribed previously (Weyrich et al., 1998) using an antibody that preferen-
tially recognizes pro–IL-1  (Research Diagnostics, Inc.).
Immunolocalization of platelet-derived IL-1 
Platelets were left quiescent or stimulated with 0.01 U/ml thrombin for 8 h
as described above. Immunocytochemistry for IL-1 , P-selectin, and poly-
merized actin was conducted as described previously (Weyrich et al.,
1996, 1998).
Figure 4. Microvesicle-derived IL-1  induces endothelial 
adhesiveness for neutrophils (PMNs) and synthesis of this 
cytokine requires engagement of  3 integrins. (A) Control plate-
lets or platelets activated with thrombin (0.1 U/ml) or PAF (1 nM) 
were incubated for 18 h. IL-1  was then measured in the fibrin-
rich cell lysates (C) or the supernatant fractions that contained 
soluble IL-1  (S) or IL-1  exported in microvesicles (MV). The 
same fractions were immunoblotted for P-selectin (P-Sel) and 
 3 integrins (inset and unpublished data). (B) A portion of the 
microvesicle fraction assayed in A, recombinant pro–IL-1 , or 
recombinant mature IL-1  was incubated with endothelial cell 
monolayers in the presence or absence of a specific IL-1  recep-
tor antagonist. After 4 h, the endothelial cells were washed, 
111In-
labeled PMNs were added, and adhesion was measured after an 
additional 30-min incubation. The data in A and B are the mean 
  SEM of three independent experiments. (C) Platelets were 
lysed immediately (Co; baseline) or incubated for 18 h alone, 
with thrombin (IIa), or with thrombin plus a control antibody 
(CoAb) or mAb c7E3 (100  g/ml). The inset illustrates platelet–
fibrin complex formation induced by thrombin in the presence of 
mAb c7E3 or the control antibody. The bar graph illustrates val-
ues for the measurements of total mature IL-1  levels by ELISA 
(mean   SEM of four independent experiments), and the asterisks 
designate P   0.05 compared with maximum IL-1  synthesis 
over 18 h (Max).490 The Journal of Cell Biology | Volume 154, 2001
Isolation of platelet microvesicles
Platelets were activated with PAF or thrombin as indicated above. After
8 h, the platelet suspensions were centrifuged for 4 min at 15,500 g. The pel-
let was lysed in RIPA buffer and the supernatant was collected and recen-
trifuged at 100,000 g in a Ti80 rotor (Beckman Coulter) for 90 min at 4 C
to collect platelet microvesicles (George et al., 1982). The resulting pellet
from high-speed centrifugation of the supernatant pool, which contained
microvesicles, was lysed in RIPA buffer. Mature IL-1  was assayed in the
pellet lysates, the microvesicle fraction, and the soluble supernatant by
ELISA. The same samples were also examined by Western analysis using
mAb S12 to detect P-selectin in the microvesicle fraction.
PMN adhesion to activated endothelial cells
Human umbilical endothelial cells were incubated with platelet superna-
tants or microvesicle fractions for 4 h in the presence or absence of a re-
combinant IL-1  receptor antagonist (R&D Systems). In parallel, human
umbilical endothelial cells were also stimulated with tumor necrosis factor
  (100 U/ml), recombinant active IL-1 , or recombinant pro–IL-1 . After
4 h, the human umbilical endothelial cells were thoroughly washed and
PMN adhesion to the cell surface was quantitated as described previously
in detail (Lorant et al., 1991; Lindemann et al., 2000).
Online supplemental material
Fig. S1(available at http://www.jcb.org/cgi/content/full/154/3/485/DC1)
demonstrates that immunostaining of platelet-derived IL-1  is quenched
when the antibodies are preincubated with purified IL-1  protein. Platelets
were prepared for immunocytochemical detection of IL-1  protein as de-
scribed in Fig. 2 A, the exception being that the anti–IL-1  antibody was
quenched with excess IL-1  protein.  The left panel depicts staining for IL-
1  with quenched antibody.  The middle panel shows the same cells
stained for actin.  The right panel is an overlay of the two panels.  Note
that staining for IL-1  is absent in the left and right panels.
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